CollPlant Biotechnologies Ltd has filed a Form 6-K outlining plans to develop a next-generation, photocurable dermal filler designed to address facial volume loss associated with rapid weight reduction, including patients treated with GLP-1 receptor agonists.
In a media release, the company said the product will be based on its proprietary recombinant human collagen, known as rhCollagen, and is intended to target what it describes as a growing aesthetic market emerging from the widespread use of GLP-1 weight-loss therapies.
Addressing post-weight-loss facial volume loss
Accelerated weight reduction linked to GLP-1 medications has been associated with visible facial fat loss in some patients, creating demand for structural volume restoration and skin support. CollPlant’s proposed filler aims to provide immediate restoration of facial contours while forming a light-activated, crosslinked collagen scaffold designed to integrate with surrounding tissue.
‘Rapid weight loss can lead to significant facial volume depletion and skin quality changes,’ said Yehiel Tal, Chief Executive Officer of CollPlant. ‘GLP-1 therapies are creating a new category of aesthetic indications. CollPlant’s photocurable filler technology was designed for structural tissue restoration – making it particularly relevant for patients experiencing rapid facial volume loss. Our photocurable rhCollagen-based filler platform is designed not only to restore facial contours, but also to provide a scaffold to support tissue regeneration and long-term structural improvement.’
According to the filing, the injectable would be photocurable, meaning it is activated in situ using a light source to create a stabilised matrix following placement. The company states this scaffold is intended not only to restore structure but also to support tissue integration and potentially contribute to longer-term skin quality improvements.
The technology remains in the preclinical stage, and timelines for clinical trials or regulatory submissions have not yet been disclosed.
Dr Jason Bloom, a double board certified facial plastic surgeon, noted: ‘We are seeing a growing number of patients presenting facial volume depletion after significant weight loss, particularly those using newer metabolic therapies. Technologies that go beyond temporary filling and instead support tissue integration and regeneration could represent an important evolution in how we approach these cases.’
